We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App





Portable, Battery-Powered Device Combined with Rapid, Highly Sensitive and Accurate Assay Enables COVID-19 Testing Anytime, Anywhere

By LabMedica International staff writers
Posted on 20 May 2021
Print article
Image: Researchers have developed a new approach to coronavirus testing, creating the first hand-held, battery-powered testing device that can yield accurate results in half an hour. The device can simultaneously test for multiple genes, researchers report (Photo courtesy of Photo by L. Brian Stauffer)
Image: Researchers have developed a new approach to coronavirus testing, creating the first hand-held, battery-powered testing device that can yield accurate results in half an hour. The device can simultaneously test for multiple genes, researchers report (Photo courtesy of Photo by L. Brian Stauffer)
A new coronavirus test can get accurate results from a saliva sample in less than 30 minutes and detect as little as one viral particle per 1-microliter drop of fluid.

Many of the components of the hand-held device used in this technology developed by researchers at the University of Illinois at Urbana-Champaign (Champaign, IL, USA) can be 3D-printed. Though it is still in the prototype stage, the device is estimated to cost less than USD 78 and the reagents and other materials needed for testing would amount to USD 6-7 per test, the researchers found.

Current coronavirus testing technologies are complex, expensive, time-consuming and require bulky equipment and expert analysts, whereas the new device can be operated by anyone with minimal training who is careful when loading samples. The innovation was made possible by their recent discovery of a system for making artificial restriction enzymes that can be programmed to recognize and cleave specific genes in an organism’s genome. In the new device, these enzymes carry DNA guides that tag the viral genes of interest. The enzyme cleaves the genes, which have been tagged with a dye that fluoresces only after the genes are cut. The resulting fluorescence signals that those genes are present – a positive test result.

The new technology, called Scalable and Portable Testing, does away with the complicated process of heating and cooling each sample to get results, as many current testing protocols require. SPOT also can detect multiple genes per sample, making it more accurate than single-gene tests, which can yield incorrect or inconclusive results. Another advantage is that it utilizes saliva, which is easier to collect and less invasive than a nasal swab.

The research team tested SPOT using 104 clinical saliva samples. They found that it accurately identified 28 out of 30 SARS-CoV-2-positive samples and 73 of 74 SARS-CoV-2-negative samples. The researchers also tested SPOT with samples containing - or lacking - the influenza virus, the new coronavirus and three other human coronaviruses. It accurately identified samples containing the new coronavirus, whether or not other viruses were present in the sample. The SPOT system also may be useful for detecting genetic markers of certain types of cancer in saliva.

“We developed a rapid, highly sensitive and accurate assay, and a portable, battery-powered device for COVID-19 testing that can be used anywhere at any time,” said University of Illinois Urbana-Champaign chemical and biomolecular engineering professor Huimin Zhao, who led the research. “One key advantage to this technology is its multiplexing capability, so in principle, we can detect many viruses simultaneously using the same device.”

Related Links:
University of Illinois at Urbana-Champaign

Gold Supplier
Sample Transport
VACUETTE Transport Line
New
Gold Supplier
Microplate Washer
MW-12A
New
Silver Supplier
Dyspeptic Diagnostic Test
GastroPanel
New
2019-nCov Neutralization Antibody Test Kit (Colloidal Gold immunochromatography)
2019-nCov Neutralization Antibody Test Kit (Colloidal Gold immunochromatography)

Print article
BIOHIT  Healthcare OY

Channels

Industry

view channel
Image: Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device (Photo courtesy of Quidel Corporation)

Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device

Quidel Corporation (San Diego, CA, USA) has received an amended Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) allowing the company to market Sofia Q, its latest addition... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.